JOHANNESBURG — If you've been thinking it seems like there are more wars raging in the world these days, it turns out you're right and the data proves it. A new study by researchers at a university in ...

In randomized trials, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improved kidney and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease (CKD).